Otsuka Pharmaceutical Co.
Otsuka Pharmaceutical Co., Ltd
2440 Research Boulevard
Rockville, MD 20850
Phone: (301) 990-0030Website: https://www.otsuka-us.com/Careers: www.otsuka-us.com/careers-our-culturePatient Assistance Program: www.otsukapatientassistance.com
Latest news
- Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
31 March 2025 - Otsuka Provides Update on Sibeprenlimab, an Investigational Monoclonal Antibody for the Treatment of IgA Nephropathy in Adults
19 November 2024 - Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy
16 February 2024 - Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application (sNDA) for Rexulti (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
10 May 2023 - FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
28 April 2023 - Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for Rexulti (brexpiprazole) to Treat Schizophrenia in Pediatric Patients Ages 13-17
6 January 2022 - FDA Approves Jynarque (tolvaptan) to Slow Kidney Function Decline in Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease
24 April 2018 - FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
13 November 2017 - U.S. FDA Approves Labeling Update of Rexulti (brexpiprazole) for Maintenance Treatment of Schizophrenia
23 September 2016 - FDA Issues Complete Response Letter for Digital Medicine New Drug Application
26 April 2016
Drugs Associated with Otsuka Pharmaceutical Co., Ltd
Otsuka Pharmaceutical Co., Ltd manufactures, markets and/or distributes more than 11 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Abilify
Generic name: aripiprazole Drug class: atypical antipsychotics |
1120 reviews | 6.1 / 10 |
|
Abilify Asimtufii
Generic name: aripiprazole Drug class: atypical antipsychotics |
1 review | 8.0 / 10 |
|
Abilify Maintena
Generic name: aripiprazole Drug class: atypical antipsychotics |
65 reviews | 6.3 / 10 |
|
Abilify MyCite
Generic name: aripiprazole Drug class: atypical antipsychotics |
||
|
Busulfex
Generic name: busulfan Drug class: alkylating agents |
||
|
Dacogen
Generic name: decitabine Drug class: antimetabolites |
||
|
Jynarque
Generic name: tolvaptan |
||
|
Nuedexta
Generic name: dextromethorphan/quinidine Drug class: miscellaneous central nervous system agents |
23 reviews | 8.9 / 10 |
|
Rexulti
Generic name: brexpiprazole Drug class: atypical antipsychotics |
447 reviews | 6.6 / 10 |
|
Samsca
Generic name: tolvaptan Drug class: vasopressin antagonists |
||
|
Sprycel
Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors |
21 reviews | 7.5 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||